United States securities and exchange commission logo





                          May 5, 2023

       James McCullough
       Chief Executive Officer
       Renalytix plc
       Finsgate
       5-7 Cranwood Street
       London EC1V 9EE
       United Kingdom

                                                        Re: Renalytix plc
                                                            Registration
Statement on Form F-3
                                                            Filed on May 2,
2023
                                                            File No. 333-271579

       Dear James McCullough:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Nicholas
O'Leary at 202-551-4451 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Industrial Applications and

                          Services
       cc:                                              Katie Kazem, Esq.